[
  {
    "PICO_IDX": "15",
    "Date": "1946-2018",
    "Ref": "1. Dhir V. Comparison of two different folic acid doses with methotrexate - a randomized controlled trial (FOLVARI Study). Arthritis Research & Therapy. 2015;17:156.",
    "PMID": "26063325",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "15",
    "Date": "1946-2018",
    "Ref": "2. Morgan Sea. Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis. Ann Intern Med. 1994;121:833-41.",
    "PMID": "7978695",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "28",
    "Date": "1946-2018",
    "Ref": "1.  Menon Nea. Comparison of Intra-articular Glucocorticoid Injections with DMARDs versus DMARDs alone in Rheumatoid Arthritis. Journal of the association of physicians of india. 2014;62:673-6.",
    "PMID": "25856933",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "1.  Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.",
    "PMID": "30832414",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "2. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.",
    "PMID": "15262104",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "3. Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.",
    "PMID": "23509040",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "4. Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.",
    "PMID": "17519278",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "5. Fransen J. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis BMJ. 2005; 64:1294–1298.",
    "PMID": "15829574",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "12a",
    "Date": "1946-2018",
    "Ref": "6. Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.",
    "PMID": "19581281",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "13",
    "Date": "1946-2018",
    "Ref": "1. Akdemir G. Comparison between low disease activity or das remission as treatment target in patients with early active rheumatoid arthritis. RMD Open. 2018;4(1).",
    "PMID": "29862045",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "1. Fleischmann R. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. The Lancet. 2017;390(10093):457.",
    "PMID": "28629665",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "2. Kaneko Y AT, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). BMJ. 2016;75:1917-23.",
    "PMID": "26733110",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "3. Dougados M. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the Rheumatic Diseases. 2014;73(5):803.",
    "PMID": "24473673",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "4. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Annals of the Rheumatic Diseases. 2009;68(7):1146.",
    "PMID": "18794178",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "5. Capell HA. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases. 2007;66(2):235.",
    "PMID": "16926184",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "6. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]. Arthritis & Rheumatism. 2006;54(9):2817.",
    "PMID": "16947782",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "7. van Riel PL. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the Rheumatic Diseases. 2006;65(11):1478.",
    "PMID": "16464988",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "8. Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, Riel PV. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Annals of the Rheumatic Diseases. 2005;64(1):44.",
    "PMID": "15271770",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "9. Edwards JC. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004;350(25):2572.",
    "PMID": "15201414",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "10. van Riel PL. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Annals of the Rheumatic Diseases. 2008;67(8):1104.",
    "PMID": "17666447",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "11. Strand V, et al. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019;5.",
    "PMID": "31673419",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "12. Breedveld FA, S.; Yin, M.; et. al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. J Clin Pharmacol. 2007;47:1119-28.",
    "PMID": "17766699",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "21a",
    "Date": "1946-2018",
    "Ref": "13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(9):1552.",
    "PMID": "9751087",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.",
    "PMID": "29900829",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.",
    "PMID": "25997746",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.",
    "PMID": "28013201",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Santos-Faria D. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi. ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA. 2019;44:103-13.",
    "PMID": "31243259",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.",
    "PMID": "17412737",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).",
    "PMID": "21328309",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Elmedany SH. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. Clin Rheumatol. 2019;38:2109-17.",
    "PMID": "30915650",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "24",
    "Date": "1946-2018",
    "Ref": "Iannazzo S, Benucci M, Favalli EG. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. Clinical & Experimental Rheumatology. 2018;36(3):479.",
    "PMID": "29352843",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.",
    "PMID": "29900829",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Manders SH, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. BioMed Central. 2015;17.",
    "PMID": "25997746",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Tarp S, Furst DE, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. [Review]. Rheumatology. 2017;56(3):417.",
    "PMID": "28013201",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "BLOMley MJ. Effectiveness of a Third Tumor Necrosis Factor-a-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. The Journal of Rheumatology. 2011;38(11):2355-61.",
    "PMID": "21885487",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.",
    "PMID": "17412737",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Singh JA WG, Christensen R, Tanjong Ghogomu E, Maxwell LJ, MacDonald JK, Filippini G, Skoetz N, Francis DK, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Cameron C, Lunn MPT, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). Cochrane Library. 2016(4).",
    "PMID": "21328309",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Elmedany SH. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. Clin Rheumatol. 2019;38:2109-17.",
    "PMID": "30915650",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "25",
    "Date": "1946-2018",
    "Ref": "Beresniak A. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clinical & Experimental Rheumatology. 2013;31(3):400.",
    "PMID": "23464803",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.",
    "PMID": "23332236",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.",
    "PMID": "25372086",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.",
    "PMID": "28666080",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.",
    "PMID": "25873634",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.",
    "PMID": null,
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.",
    "PMID": "27252426",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).",
    "PMID": "25858265",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Smolen JS. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.[Erratum appears in Lancet. 2014 Jan 25;383(9914):308]. Lancet. 2014;383(9914):321.",
    "PMID": "24168956",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Pablos JL. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study. Clinical & Experimental Rheumatology. 2019;37:437-44.",
    "PMID": "30299241",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Moghadam MG. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity. ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1810-7.",
    "PMID": "26866428",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Pavelka K. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access. Rheumatology International. 2017;37(9):1469.",
    "PMID": "28597306",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "52",
    "Date": "1946-2018",
    "Ref": "Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, et al. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases. 2016;75(11):1939.",
    "PMID": "26764260",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.",
    "PMID": "25372086",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.",
    "PMID": "28666080",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.",
    "PMID": "27252426",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Sanmarti R. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. Arthritis & Rheumatism. 2019;71(10):1616-25.",
    "PMID": "31087542",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.",
    "PMID": "26103979",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Miedany Y. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol. 2016;35:2915–23.",
    "PMID": "27658417",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Chatzidionysiou K. A multicentre, randomised, controlled,open-label pilot study on the feasibilityof discontinuation of adalimumab inestablished patients with rheumatoidarthritis in stable clinical remission. 2016;2.",
    "PMID": "26819752",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "53",
    "Date": "1946-2018",
    "Ref": "Aletaha D, Snedecor SJ, Ektare V, Xue M, Bao Y, Garg V. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-a inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. ClinicoEconomics and Outcomes Research. 2017;9:451-8.",
    "PMID": "28814890",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54a",
    "Date": "1946-2018",
    "Ref": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.",
    "PMID": "23332236",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54a",
    "Date": "1946-2018",
    "Ref": "Chatzidionysiou K. A multicentre, randomised, controlled,open-label pilot study on the feasibilityof discontinuation of adalimumab inestablished patients with rheumatoidarthritis in stable clinical remission. 2016;2.",
    "PMID": "26819752",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54a",
    "Date": "1946-2018",
    "Ref": "van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ (Online). 2015;350(no pagination).",
    "PMID": "25858265",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54a",
    "Date": "1946-2018",
    "Ref": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.",
    "PMID": null,
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54b",
    "Date": "1946-2018",
    "Ref": "Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases. 2016;75(1):59.",
    "PMID": "26103979",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54b",
    "Date": "1946-2018",
    "Ref": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.",
    "PMID": "25873634",
    "Dataset": "2021 ACR RA"
  },
  {
    "PICO_IDX": "54b",
    "Date": "1946-2018",
    "Ref": "Moghadam MG. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity. ARTHRITIS & RHEUMATOLOGY. 2016;68(8):1810-7.",
    "PMID": "26866428",
    "Dataset": "2021 ACR RA"
  }
]